|
IPM reports 8% growth during 3rd quarter of the year: IQVIA report
|
|
Our Bureau, New Delhi
November 30 , 2022
|
|
|
The overall Indian Pharmaceutical Market (IPM) has reported an eight per cent growth during the third quarter of the calendar year 2022, ending September, at Rs. 51,880 crore as compared to around 48,000 in the same quarter last year, according to a report from analytics major IQVIA.
The IPM has seen a higher growth in the third quarter compared to the second quarter of the year which reported around Rs. 47,000 crore, and first quarter which was around Rs. 44,000 crore. The overall IPM market size in the month of September was seven per cent up from the previous month, at Rs. 1,89,117 crore monthly average total (MAT), with seven per cent growth from around Rs. 1,77,000 crore in the previous year.
The acute market reflected a growth of seven per cent majorly due to the growth from anti-infectives, pain management and gastro-intestinal therapies. The anti-infectives market reported a growth of seven per cent in value compared to the same period of previous year, while compared to the sequential quarter ended June, 2022 it has registered a 35 per cent growth, said the IQVIA report.
Cephalosporins, which contributes to around 44 per cent of the total anti-infectives therapy, grew by seven per cent growth, macrolides and quinolones grew in single digit at two per cent and one per cent respectively.
Pain management segment grew 10 per cent in terms of value compared to the same quarter of last year, while compared to sequential quarter, value grew by 15 per cent. Gastro intestinal segment saw value growth of 12 per cent compared to the same quarter last year, while the growth in the sequential quarter was stagnant, with a decline of 10 per cent in unit sales, it added.
Anti-diabetes market showed the highest number of new launches in sitagliptin and its combination market during the quarter from July to September, this year, owing to the drug going off patent in the country.
Driven by the growth from cardiac, anti-diabetes, neuro and respiratory segments, the chronic therapies displayed a growth of 11 per cent compared to previous period growth (PPG). Cardiac segment grew 10 per cent in value compared to previous period, while on a comparison of sequential performance, it was two percent growth in value. Statins and hyptensives grew 13 per cent (PPG) and14 per cent (PPG), and together contributed to around 38 per cent of the total sales in the segment.
Chronic respiratory segment has reported the highest growth in the chronic therapies at 12 per cent growth in terms of value compared to the previous period, and 20 per cent sequential quarter growth. Montelukast and its combination market grew at 13 per cent PPG during the period.
The domestic pharma companies reflected a faster growth of around nine per cent PPG compared to the five per cent PPG reported by the MNC companies. Sun Pharma, Cipla, Mankind and Alkem reflected growth among top Indian pharma companies while Abbott, GSK, P&G, and Janssen reflected growth among top multinational pharma companies, said the report.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|